Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress

Stock Information for Organovo Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Organovo Holdings Inc.

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
CORRECTION - Organovo Highlights FXR314 Combination Therapy Potential and Plan
Organovo Highlights FXR314 Combination Therapy Potential and Plan
Organovo to Participate in the H.C. Wainwright Global Investment Conference
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
Organovo Announces FXR Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.